Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech Inc. announced that the FDA granted Orphan Drug Designation for its drug Ampligen (rintatolimod) to treat pancreatic cancer, a disease with a low five-year survival rate of just 6%. This designation provides seven years of market exclusivity upon approval. The company also reported statistically significant survival results from a study at Erasmus University, showing a median survival rate approximately 200% higher in patients treated with Ampligen compared to a historical control group. This suggests potential for extended survival rates against the standard care for pancreatic cancer.
AIM ImmunoTech Inc. (NYSE American: AIM) reports progress in developing treatments for COVID-19, with its collaboration in a Phase 1/2a study at Roswell Park Comprehensive Cancer Center for a two-drug regimen involving Ampligen and interferon alpha-2b. The study is underway, with the first patient treated. AIM is also focusing on intranasal prophylaxis for high-risk groups and therapies for COVID-19 Long Haulers. AIM emphasizes the need for early treatments amid vaccine developments from major pharmaceutical firms. The company remains committed to advancing its research efforts.
AIM ImmunoTech (AIM) reported third-quarter financials on November 13, 2020. Cash and equivalents surged to $54.5 million from $8.8 million at year-end 2019. Research expenses fell slightly to $1.10 million, while general expenses rose to $2.09 million. Clinically, AIM revealed promising pancreatic cancer survival data, with median survival improving by 200% for patients treated with Ampligen compared to historical controls. Additionally, significant findings were reported for ME/CFS and COVID-19, with Ampligen showing potential benefits for early-stage patients.
AIM ImmunoTech announced the publication of significant data indicating that its drug Ampligen may effectively treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) when used early. The research, published in PLOS ONE, revealed that 51.2% of Ampligen-treated ME/CFS patients improved their exercise duration by at least 25%. The company has expanded its AMP-511 Early Access Program to include 'Long Haulers' from COVID-19, suggesting a potential benefit from early treatment. Amidst this, AIM emphasizes the need for further research to validate these findings.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in a virtual panel titled “COVID-19: Progress on Treatments & Prevention” on October 29 at 10:05 A.M. ET during the 23rd Annual BioFlorida Conference. The conference will feature discussions by global experts on BioPharma, MedTech, HealthIT, and COVID-19. Attendees can access the live webcast via the conference platform. AIM ImmunoTech is dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech has received IRB approval for an expanded access clinical trial of Ampligen to treat chronic fatigue-like symptoms in COVID-19 patients, also known as Long Haulers. The updated protocol allows for 20 out of 100 participants to include those who have been diagnosed with SARS-CoV-2 but still show symptoms. AIM anticipates a rise in Chronic Fatigue Syndrome (CFS) cases post-COVID-19 and is preparing to submit the IRB-approved protocol to the FDA. This also follows a provisional patent application for Ampligen as a therapy for COVID-19-induced ME/CFS-like illnesses.
AIM ImmunoTech announced statistically significant positive results in pancreatic cancer survival from an Early Access Program at Erasmus University Medical Center. The median survival increased by approximately 200% for patients treated with Ampligen compared to historical controls. AIM aims to seek FDA Fast Track designation and orphan drug status for Ampligen as a treatment for late-stage pancreatic cancer. The company will collaborate with Amarex Clinical Research to initiate a Phase 2/3 clinical trial in the Netherlands and the U.S., seeking to extend exclusivity rights for Ampligen.
AIM ImmunoTech Inc. (NYSE American:AIM) announced the start of recruitment for a Phase 1/2a clinical trial at Roswell Park Comprehensive Cancer Center. The trial investigates the use of rintatolimod (Ampligen) combined with interferon alpha-2b for cancer patients with mild to moderate COVID-19. This study aims to leverage 20 years of cancer immunotherapy research to engage the innate immune system against SARS-CoV-2 and other RNA viruses. The trial is funded with support from the National Cancer Institute and AIM.
AIM ImmunoTech Inc. (NYSE American:AIM) will present at the H.C. Wainwright Annual Global Investment Conference from September 14-16, 2020. CEO Thomas K. Equels is set to deliver a presentation on September 14 at 5:00 p.m. ET, which will be available via live webcast. The company focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American:AIM) announced that CEO Thomas K. Equels will participate in the virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs" on September 10, 2020, at 1:00 p.m. ET. The panel features executives from prominent biopharmaceutical firms discussing their strategies to combat the COVID-19 pandemic. Moderated by journalist Christine Corrado, the event aims to inform investors about advancements in treatment. AIM is known for its research in immune disorders and viral diseases, particularly for its key products, Ampligen® and Alferon N Injection®.
FAQ
What is the current stock price of AIM ImmunoTech (AIM)?
What is the market cap of AIM ImmunoTech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
